je.st
news
Tag: merck
Exclusive: Merck works toward bringing Zilmax back to the U.S., Canada market
2013-10-30 05:33:12| Food - Topix.net
Our day's top images, in-depth photo essays and offbeat slices of life. See the best of Reuters photography.
Merck Announces Presentation of Interim Data from Phase 1B Study of MK-3475, Investigational anti-PD-1 Immunotherapy, in Previously-Treated Patients with Non-Small Cell Lung Cancer (NSCLC) at 15th World Conference on Lung Cancer
2013-10-29 06:15:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. Phase II/III Trial of MK-3475 in Patients with NSCLC Currently Enrolling WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of interim data from a Phase 1B trial (PN001) evaluating MK-3475, an investigational anti-PD-1 immunotherapy, in patients with previously-treated non-small cell lung cancer (NSCLC). The data were presented today by Dr. Language: English Contact: MerckMedia Contacts:Ian McConnell, 908-423-3046orClaire Mulhearn, 908-423-7425orInvestor Contacts:Carol Ferguson, 908-500-1101orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Merck profits fall, Loews up
2013-10-29 03:54:27| Grocery - Topix.net
A pedestrian walks outside a Merck & Co. facility in Summit, N.J. The company's earnings reflected competitive pressure from generic-drug makers.
Tags: fall
profits
merck
loews
Merck 3Q net income falls on charges, lower sales
2013-10-28 16:30:31| Biotech - Topix.net
Merck & Co. said Monday that its third-quarter profit plunged 35 percent because of competition from generic drugs, lower sales of its top-selling medicine, and restructuring and acquisition charges.
Merck Announces Third-Quarter 2013 Financial Results
2013-10-28 12:00:00| Merck.com - Corporate News
Dateline City: WHITEHOUSE STATION, N.J. 2013 Third-Quarter Non-GAAP EPS of $0.92, Excluding Certain Items; GAAP EPS of $0.38 Worldwide Sales were $11.0 Billion, a Decrease of 4 Percent Reflecting the Unfavorable Impact of Patent Expiries and a 2 Percent Negative Impact from Foreign Exchange Strong Growth in Vaccines and Immunology as well as ISENTRESS Breakthrough Therapy Designation Granted for MK-5172/MK-8742, in Development for the Treatment of Chronic Hepatitis C Virus Infection; V503, Mercks Investigational 9-valent HPV Vaccine has Completed Pivotal Phase III Study, on Track for 2013 Submission Narrows Full-Year Non-GAAP EPS Target to $3.48 to $3.52; GAAP EPS Target to $1.61 to $1.79 WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced financial results for the third quarter of 2013. $ in millions, except EPS amounts ThirdQuarter2013 ThirdQuarter2012 Language: English Contact: MerckMedia Contacts:Kelley Dougherty, 908-423-4291Steven Cragle, 908-423-3461orInvestor Contacts:Carol Ferguson, 908-423-4465Joe Romanelli, 908-423-5185 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: results
financial
announces
merck
Sites : [100] [101] [102] [103] [104] [105] [106] [107] [108] [109] [110] [111] [112] [113] [114] [115] [116] [117] [118] [119] next »